Galactionova, Katya
Salari, Paola
Mattli, Renato
Rachamin, Yael
Meier, Rahel
Schwenkglenks, Matthias http://orcid.org/0000-0001-7217-1173
Funding for this research was provided by:
Novartis
University of Basel
Article History
Accepted: 1 May 2022
First Online: 20 June 2022
Change Date: 30 August 2022
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note
Change Date: 7 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40273-022-01171-5
Declarations
:
: Open access funding provided by University of Basel.
: MS received research funding from Novartis via an employment institution and, unrelated to the work reported in the article, remuneration for participation in advisory boards from Amgen and Sandoz. RM received research funding from Novartis and Amgen via an employment institution unrelated to the work reported in the article.
: Not applicable.
: Not applicable.
: Not applicable.
: The parameters values used in the modelling study are included in the published article (and its supplementary information files) or are available from the corresponding author on reasonable request for non-commercial purposes, as is the model. Access to underlying data from the Swiss Federal Office of Statistics, the FIRE database and the Global Burden of Disease project is possible via the data owners, following their regulations. Where relevant, contact can be established with the corresponding author.
: The model was implemented in TreeAge and is available from the corresponding author (MS) on reasonable request for non-commercial purposes.
: MS conceived and designed the study. MS developed and implemented the model in TreeAge, and performed the model validation. KG, PS and RM contributed to the study design and model development. MS, KG and PS performed the analysis. KG and PS collated data and derived model inputs. RM collated data and derived unit costs. YR and RM provided aggregate FIRE data on patient characteristics, treatments and events in secondary cardiovascular prevention patients. KG and MS drafted the manuscript. All authors reviewed the manuscript for important intellectual content and approved the final version.